Hebrew University and TechforCann Europe Accelerator to Collaborate on Funding Medical Cannabis Research Companies Worldwide

JERUSALEM, ISRAEL… January 14, 2022 — The Hebrew University of Jerusalem’s (HU) Technology Transfer Company, Yissum, together with the TechforCann Europe Accelerator, announces a strategic collaboration with TechforCann, Europe’s first medical cannabis tech accelerator, to fund startups around the world.

Researchers at HU’s Multidisciplinary Center for Cannabinoid Research, (MCCR) will serve as advisory board members, mentors, and potential candidates for the startups that are accepted into the TechforCann Europe Accelerator program. The HU Medical Cannabis online curriculum will also be available to international audiences through the accelerator platform. TechforCann will have access to a pipeline of innovative research projects that will benefit from the acceleration program. The parties will collaborate on licensing or co-development of new products.

HU’s MCCR, one of the world’s few cannabis incubators, conducts breakthrough research on cannabinoids, endocannabinoids, and medical cannabis. It focuses on solutions to address cancer, pain management, inflammation and stress management, immunity, metabolism, nano drug delivery, pharmaceutical chemistry, neuroscience, plant science and genetics.

TechforCann is the first accelerator to focus on medical cannabis technologies in Europe. The accelerator identifies and nurtures early-stage IP based companies with potential for exit/IPO. The hybrid acceleration program focuses on entrepreneurs who are solving challenges across the supply chain, with a focus on healthcare and biotech, digital health, precision agriculture, and new product technologies. Established by two Israel-based female co-founders Lilac Mandeles and Yona Cymerman –the TechforCannEU accelerator program allows entrepreneurs to reach milestones faster, with less error and expense, ultimately increasing their probability of commercial success.

“One of our major objectives at MCCR is to foster collaborations between our own teams and other groups worldwide who are conducting medical cannabis research,” said HU Prof. of Pharmacology Yossi Tam, MCCR director and head of the Obesity & Metabolism Laboratory. “A key priority is a cannabis-based synthetic active pharmaceutical ingredient (API) that may change people’s lives. For example, we have recently completed pre-clinical work with a synthetic derivative of cannabinoid-acid, demonstrating its efficacy in treating obesity, and we have a lot more research in the pipeline.”

“Partnering with such important and world-breaking institutions such as Yissum and the MCCR validates our goal of supporting early-stage IP based startups from around the world who are solving challenges across the medical cannabis supply chain,” says Lilac Mandeles, CEO of TechforCann. “We are excited to nurture and promote top-tier research that is currently being conducted, as well as offer our startups access to world-leading clinicians and researchers as well as cut the time to market for these remarkable innovations.”

For more information: www.techforcanneurope.com

About Yissum

Yissum is the technology transfer company of The Hebrew University of Jerusalem (HU). Founded in 1964, it serves as a bridge between cutting-edge academic research and a global community of entrepreneurs, investors, and industry. Yissum’s mission is to benefit society by converting extraordinary innovations and transformational technologies into commercial solutions that address our most urgent global challenges. Yissum has registered over 10,875+ patents globally; licensed over 1140+ technologies and has spun out more than 191 companies. Yissum’s business partners span the globe and include companies such as Boston Scientific, Google, ICL, Intel, Johnson & Johnson, Merck, Microsoft, Novartis and more. For more information, please visit www.yissum.co.il.

About the Hebrew University of Jerusalem

The Hebrew University of Jerusalem is Israel’s leading academic and research institution. Serving 23,000 students from 80 countries, it produces a third of Israel’s civilian research and is ranked 12th worldwide in biotechnology patent filings and commercial development. Faculty and alumni of the Hebrew University have won eight Nobel Prizes and a Fields Medal since 2000. The Hebrew University has 302 academic agreements with institutions in 44 countries; 78 competitive research grants from the European Research Council (ERC) since 2007; student exchange agreements with 56 institutions in 24 countries; 90 courses for the study of some 30 languages; 177 postdoctoral researchers from 26 countries; and an annual enrollment of approximately 2,000 students from 80 countries at the Rothberg International School. For more about the Hebrew University, see http://new.huji.ac.il/en.

About American Friends of the Hebrew University

American Friends of the Hebrew University (AFHU) is a national, not-for-profit organization based in the United States. AFHU is headquartered in New York and has six regional offices working in close partnership with the Hebrew University of Jerusalem. AFHU provides supporters, Hebrew University alumni and the general public with stimulating programs and events and organizes missions to Israel. The organization’s fundraising activities support scholarly and scientific achievement at the Hebrew University, create scholarships, new facilities and assist the university’s efforts to recruit outstanding new faculty. For more information, please visit http://www.afhu.org/.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.